Thus, the combination of VEGF inhibitors following TACE could, theoretically, regulate the expressions of cancer-promoting factors, e.g. VEGF and MMP-9, inhibit angiogenesis of tumors, and eventually reduce the possibility of tumor recurrence and metastasis. The gene discussed is VEGFA; the disease is cancer.